Two cancer patients—Stephen Estrada and Mary Elizabeth Williams—discuss how they regained control after their cancer diagnosis
Dr. Gavin Dunn of Washington University in St. Louis discusses how cancer vaccines are capable of educating patients’ immune systems and have the potential to improve the immune system’s ability to target and eliminate cancer.
Dr. Kunle Odunsi of the Roswell Park Comprehensive Cancer Institute discusses how biomarkers are used to help patients today as well as how we’re working to harness the full potential of biomarkers moving forward.
Dr. Philip Greenberg of the University of Washington discusses how cutting-edge strategies using T cells from patients’ blood are currently being used in the clinic as well as how they might be improved moving forward.
Ariella Chivil, a patient advocate, and Dr. Alexander M. Lesokhin, her oncologist, discuss the nuances of communicating and informing both doctor and patient while on immunotherapy.
Dr. John Bell of the University of Ottawa and the Ontario Institute for Cancer Research discussses strategies that re-program viruses so that they selectively infect and kill cancer cells while leaving healthy cells and tissues unharmed.
Cancer patients T.J. Sharpe and Donna Fernandez share their experiences with immunotherapy and advice for patients currently seeking or receiving immunotherapy treatment.
Patrick Meins of EmergingMed will answer common questions around cancer clinical trials including trial definitions, eligibility criteria, and how to search for the right one.
Dr. James P. Allison of MD Anderson discusses how some proteins in immune cells act as "brakes" on the immune system response and how checkpoint inhibitors can be used to “release the brakes,” allowing a stronger immune attack against cancer.
Dr. Jedd D. Wolchok of Memorial Sloan Kettering Cancer Center discusses the latest developments in patient care including: checkpoint blockade, cancer vaccines, combination therapies, CAR T cell therapy, T cell receptor therapies, and neoantigens.
Dr. John B. Liao of the University of Washington discusses the immunotherapy landscape for patients with ovarian cancer.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate tumors after checkpoint immunotherapy treatment even in the absence of T cells.
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14, seeks to improve the design and application of combination immunotherapies for patients